Although uptake was initially modest due to cost, insurance coverage, and administration requirements, use has been expanding as both patients and providers seek alternatives to injections
Patients taking other B-vitamin supplements or multivitamin preparations should inform their prescribing provider, as evaluation for potential additive effects or imbalances may be appropriate
Interestingly, W-24 (106), a non-peptide GLP-1RA, has been reported to inhibit inflammatory pain by stimulating the spinal cord GLP-1R for the release of analgesic -endorphin
The FAERS database also revealed 41 reported cases for semaglutide with an ROR of 11.36 (95% CI, 8.33 to 15.49) and a PRR of 11.36 (95% CI, 8.32 to 15.47), suggesting a potential causal relationship between semaglutide and NAION [98]
Always observe for any adverse reactions throughout the cycle